title: Cutaneous complications of molecular targeted therapy used in oncology.
abstract: The new molecular targeted therapy has been developed over the past decades by using the molecular targeted molecular changes discovered in specific types of cancer. Unfortunately, most of these agents (epidermal growth factor receptors, multi-targeted small molecule tyrosine kinase inhibitors, monoclonal antibodies) have severe cutaneous adverse reactions, that not only interfere with the patient's quality of life, but also are dose-limiting and may require treatment interruptions. These cutaneous complications and their management must be very well known by any oncologist and dermatologist who treat oncologic patients.
  
  
  BACKGROUND
  EGFR = epidermal growth factor receptors, EGFRI = epidermal growth factor receptors inhibitors.
authors.affiliation: Department of Dermatology, "Elias" University Hospital, Bucharest, Romania.
authors.forename: I
authors.initials: I
authors.lastname: Lupu
authors.affiliation: Department of Dermatology, "Elias" University Hospital, Bucharest, Romania; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
authors.forename: N
authors.initials: N
authors.lastname: Voiculescu
authors.affiliation: "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
authors.forename: N
authors.initials: N
authors.lastname: Bacalbasa
authors.affiliation: Department of Dermatology, "Elias" University Hospital, Bucharest, Romania.
authors.forename: I
authors.initials: I
authors.lastname: Cojocaru
authors.affiliation: Bucharest University Emergency Hospital, Bucharest, Romania.
authors.forename: V
authors.initials: V
authors.lastname: Vrancian
authors.affiliation: Department of Dermatology, "Elias" University Hospital, Bucharest, Romania; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
authors.forename: C
authors.initials: C
authors.lastname: Giurcaneanu
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009369:Neoplasms / Q000188:drug therapy*; D011788:Quality of Life
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: cutaneous adverse reactions; inhibitors of EGF receptors, oncology; molecular targeted therapy